Roivant Sciences Ltd. (ROIV)
10.69
0.13 (1.23%)
At close: Feb 18, 2025, 3:59 PM
10.50
-1.78%
After-hours: Feb 18, 2025, 05:19 PM EST
undefined% (undefined)
| Bid | 10.11 |
| Market Cap | 7.63B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -10.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.89 |
| Volume | 2,650,801 |
| Avg. Volume (20D) | 4,665,116 |
| Open | 10.56 |
| Previous Close | 10.56 |
| Day's Range | 10.55 - 10.81 |
| 52-Week Range | 9.76 - 13.05 |
| Beta | undefined |
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2020
Employees 908
Stock Exchange NASDAQ
Ticker Symbol ROIV
Website https://roivant.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 68.38% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
Next Earnings Release
Roivant Sciences Ltd. is scheduled to release its earnings on May 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+6.69%
Roivant Sciences shares are trading higher after t...
Unlock content with
Pro Subscription
10 months ago
+4.7%
Roivant Sciences shares are trading higher after the company announced results from its NEPTUNE Phase 2 study of brepocitinib. The company's board also authorized a share repurchase program of up to $1.5 billion, including the repurchase of all 71.3 million shares held by Sumitomo Pharma.
